Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Arunachalam

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Medrxiv : the Preprint Server for Health Sciences|April 14, 2021
mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognitionKatharina Röltgen, Sandra C A Nielsen, Prabhu S Arunachalam, et al.
Cellular & Molecular Immunology|January 5, 2022
Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primatesStéphane Pillet, Prabhu S Arunachalam, Guadalupe Andreani, et al.
Science Translational Medicine|January 13, 2022
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudovirusesBenjamin L Sievers, Saborni Chakraborty, Yong Xue, et al.
Science Translational Medicine|July 31, 2024
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primatesPrabhu S Arunachalam, NaYoung Ha, S Moses Dennison, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2Yupeng Feng, Meng Yuan, John M Powers, et al.
Elife|October 14, 2022
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyZicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Immunity|March 30, 2023
Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infectionFei Gao, Vamsee Mallajosyula, Prabhu S Arunachalam, et al.
Science Translational Medicine|May 10, 2023
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccineYupeng Feng, Meng Yuan, John M Powers, et al.
NPJ Vaccines|May 23, 2022
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in miceLilit Grigoryan, Audrey Lee, Alexandra C Walls, et al.
Cell Reports|August 21, 2022
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and miceAlexandra C Walls, Laura A VanBlargan, Kai Wu, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Medrxiv : the Preprint Server for Health Sciences|April 14, 2021
mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognitionKatharina Röltgen, Sandra C A Nielsen, Prabhu S Arunachalam, et al.
Cellular & Molecular Immunology|January 5, 2022
Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primatesStéphane Pillet, Prabhu S Arunachalam, Guadalupe Andreani, et al.
Science Translational Medicine|January 13, 2022
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudovirusesBenjamin L Sievers, Saborni Chakraborty, Yong Xue, et al.
Science Translational Medicine|July 31, 2024
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primatesPrabhu S Arunachalam, NaYoung Ha, S Moses Dennison, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2Yupeng Feng, Meng Yuan, John M Powers, et al.
Elife|October 14, 2022
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyZicheng Hu, Kattria van der Ploeg, Saborni Chakraborty, et al.
Immunity|March 30, 2023
Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infectionFei Gao, Vamsee Mallajosyula, Prabhu S Arunachalam, et al.
Science Translational Medicine|May 10, 2023
Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccineYupeng Feng, Meng Yuan, John M Powers, et al.
NPJ Vaccines|May 23, 2022
Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in miceLilit Grigoryan, Audrey Lee, Alexandra C Walls, et al.
Cell Reports|August 21, 2022
Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and miceAlexandra C Walls, Laura A VanBlargan, Kai Wu, et al.
Pageof 8